scholarly journals Giant Cell Tumor of the Sphenoid Bone

1977 ◽  
Vol 4 (3) ◽  
pp. 213-216 ◽  
Author(s):  
Rasikbala Doshi ◽  
Abdul Basit Chaudhari ◽  
Gordon Thomson
Keyword(s):  
Differential Diagnosis ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Sphenoid Bone ◽  
Histological Features ◽  
Symptoms And Signs

SUMMARY:The clinical and histological features of two cases of giant cell tumor of the sphenoid bone are described. Both presented with similar symptoms and signs, comparable to previously described cases. The problems in histological differential diagnosis are discussed and radiotherapy as the treatment of choice is suggested.

Giant-cell tumor of the sphenoid bone

1983 ◽  
Vol 59 (2) ◽  
pp. 322-327 ◽  
Author(s):  
James T. Wolfe ◽  
Bernd W. Scheithauer ◽  
David C. Dahlin
Keyword(s):  
Differential Diagnosis ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
World Literature ◽  
Bone Cyst ◽  
Cell Tumor ◽  
Sphenoid Bone ◽  
Visual Field Defects ◽  
Brown Tumor ◽  
Postoperative Radiation Therapy

✓ Giant-cell tumor rarely affects the sphenoid bone. Ten cases of this tumor seen at the Mayo Clinic are reviewed, bringing the number of cases in the world literature to 31. These tumors, which present in the second and third decades of life and are slightly more frequent in women than in men, may present with various symptoms, including headache, visual field defects, blindness, and diplopia. The symptom complex and roentgenographic findings are seldom, if ever, sufficiently characteristic to allow preoperative diagnosis. The microscopic differential diagnosis of giant-cell tumor of the sphenoid region includes giant-cell reparative granuloma, aneurysmal bone cyst, fibrous dysplasia, and “brown tumor” of hyperparathyroidism. Interesting features of this series include the presence of multifocal giant-cell tumor in one case, and the absence of Paget's disease of bone in every case. Complete follow-up review in these cases allowed a discussion of therapy and prognosis; it appears that subtotal excision with postoperative radiation therapy is the treatment of choice. While the histological appearance of giant-cell tumor is characteristic, caution must be exercised in interpreting small samples, and various reparative and metabolic disorders must be considered in the differential diagnosis.

Sphenoid bone: a rare site for giant cell tumor – case report with literature review

2016 ◽  
Vol 35 (11) ◽  
pp. 385-388 ◽  
Author(s):  
Debajyoti Chatterjee ◽  
Kirti Gupta ◽  
Navneet Singla ◽  
Ankur Kapoor
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Sphenoid Bone ◽  
Rare Site

Giant cell tumor of bone in a patient with diagnosis of primary hyperparathyroidism: a challenge in differential diagnosis with brown tumor

2013 ◽  
Vol 43 (5) ◽  
pp. 693-697 ◽  
Author(s):  
Barbara Rossi ◽  
Virginia Ferraresi ◽  
Maria Luisa Appetecchia ◽  
Mariangela Novello ◽  
Carmine Zoccali
Keyword(s):  
Differential Diagnosis ◽  
Primary Hyperparathyroidism ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Brown Tumor

scholarly journals Analysis of High-Frequency Ultrasound in the differential Diagnosis of Lumps in Foot and Hand

2020 ◽  
Vol 4 (4) ◽  
Author(s):  
Huitong Yan ◽  
Heying Li ◽  
Jianmei Han ◽  
Jianmei Han ◽  
Yingbo Tang
Keyword(s):  
Differential Diagnosis ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Epidermoid Cyst ◽  
High Frequency ◽  
Preoperative Diagnosis ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
High Frequency Ultrasound ◽  
Frequency Ultrasound

Objective: To investigate the ultrasonogram characteristics of common lumps in hand and foot, pursuing for greater understanding of hand and foot lumps. Methods: 65 cases of ultrasonographic characteristics of lumps in hand and foot were retrospectively analyzed, including the location, size, shape, boundary, internal echo and posterior echo, surrounding relationship and blood flow. Results: Among 65 cases, there were 26 cases of tendon sheath cyst, 16 cases of tenosynovitis giant cell tumor, 10 cases of hemangioma, 4 cases of tendon sheath fibroma, 3 cases of epidermoid cyst, 2 cases of Schwannoma, 2 cases of fibrolipoma, 1 case of angiolipoma and 1 case of neurofibroma. The preoperative and postoperative pathological diagnoses of 45 cases, accounting for 69.23%, were consistent, 3 cases (4.62%) were misdiagnosed, which included that 2 cases of tenosynovitis giant cell tumor were misdiagnosed as tendon sheath cyst, 1 case of neurofibroma as epidermoid cyst, and the preoperative diagnosis of the rest 17 cases(26.15%) were indefinite. Conclusion: The high-frequency ultrasound can diagnose properties of lumps in foot and hand well, providing diagnosis basis for further treatment in clinic.

scholarly journals Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report

2020 ◽  
Vol 11 ◽  
pp. 370
Author(s):  
Motoki Tanikawa ◽  
Hiroshi Yamada ◽  
Tomohiro Sakata ◽  
Mitsuhito Mase
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Sphenoid Bone ◽  
Current Case ◽  
Endoscopic Endonasal ◽  
Subcutaneous Injections ◽  
Dosing Interval ◽  
Monthly Dosing ◽  
Denosumab Treatment

Background: In the treatment of giant cell tumor of bone (GCTB), the efficacy and safety of denosumab, a receptor activator nuclear factor κ-B ligand inhibitor, has previously been demonstrated, especially for unresectable tumors. One of the current issues in denosumab treatment for unresectable GCTB is whether it can be discontinued, or whether the dosage or the dosing interval can safely be adjusted, if discontinuation is not possible, to avoid the occurrence of side effects. Case Description: A 15-year-old boy with diplopia was referred to our hospital after a space-occupying lesion in the sphenoid bone was found on head CT. Partial removal of the tumor was performed through an endoscopic endonasal approach, and pathological diagnosis was confirmed as GCTB. Thereafter, the patient received 120 mg subcutaneous injections of denosumab every 28 days for the first 2 years. Since bone formation was induced and sustained along with tumor reduction, the dosing interval was gradually extended, with 4 monthly dosing for the next 1 year, followed by 6 monthly dosing for the succeeding 2 years. With the extension of the dosing interval, the ossified tumor has regrown slightly, but within an acceptable range. Conclusion: Discontinuation of denosumab treatment for unresectable GCTB was not thought to be possible for the current case due to the nature of the drug, as reported in the literature. Extending the dosing interval up to 6 monthly, as could be done safely in the current case, can be considered a useful and appropriate measure.

Sign in / Sign up

Export Citation Format

Share Document